menu search

RVVTF / Revive Therapeutics touts publication of positive research data with Bucillamine in coronavirus

Revive Therapeutics touts publication of positive research data with Bucillamine in coronavirus
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced the publication of a scientific article evaluating the impact of medication, including Bucillamine, on antibody response to SARS-CoV-2 mRNA vaccines in Japanese patients with rheumatic diseases. The article titled, "Antibody Response to SARS-CoV-2 mRNA Vaccines in Patients with Rheumatic Diseases in Japan: Interim Analysis of a Multicenter Cohort Study", is published in Modern Rheumatology. Read More
Posted: Apr 18 2022, 11:44
Author Name: Proactive Investors
Views: 110819

RVVTF News  

Revive Therapeutics files patent application to treat chemical warfare agents exposure

By Proactive Investors
July 28, 2023

Revive Therapeutics files patent application to treat chemical warfare agents exposure

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF). said it has filed a provisional patent application for the use of Bucillamine as a potential treatment more_horizontal

Revive Therapeutics' study on safety and efficacy of Bucillamine to treat COVID 19 shows no statistical significance

By Proactive Investors
July 6, 2023

Revive Therapeutics' study on safety and efficacy of Bucillamine to treat COVID 19 shows no statistical significance

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said the results of its Phase 3 clinical trial evaluating the safety and efficacy of oral Bucillamine i more_horizontal

Revive Therapeutics' experimental COVID treatment fails in late-stage study

By Reuters
July 6, 2023

Revive Therapeutics' experimental COVID treatment fails in late-stage study

Canada-based Revive Therapeutics said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study. more_horizontal

Revive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDA

By Proactive Investors
May 30, 2023

Revive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDA

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued an update on the Phase 3 trial of its drug Bucillamine in patients with mild to moderate COV more_horizontal

Revive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next steps

By Proactive Investors
May 12, 2023

Revive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next steps

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) saidĀ its Phase 3 clinical trial evaluating Bucillamine, an oral drug with anti-inflammatory and antivi more_horizontal

Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial

By Proactive Investors
May 2, 2023

Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has revealed that the independent Data and Safety Monitoring Board (DSMB) meeting for its Bucillamine P more_horizontal

Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients

By Proactive Investors
April 19, 2023

Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has said it will review the next steps for the Phase 3 clinical trial of Bucillamine, its oral anti-inf more_horizontal


Search within

Pages Search Results: